Turkiye Klinikleri Journal of Dermatology

.: REVIEW
Dermatolojik Hastalıklarda Fitoterapi Uygulamaları
Phytotherapy Applications in Dermatological Diseases
Ülker GÜLa
aSağlık Bilimleri Üniversitesi Gülhane Tıp Fakültesi, Deri ve Zührevi Hastalıkları ABD, Ankara, TÜRKİYE
Turkiye Klinikleri J Dermatol. 2021;31(1):36-44
doi: 10.5336/dermato.2020-73866
Article Language: TR
Full Text
ÖZET
 Dermatolojik hastalıkların bir kısmı kronik seyirlidir. Geleneksel ve tamamlayıcı tedavi yöntemlerine eğilim, kronik deri hastalıklarında daha yüksektir. Geleneksel ve tamamlayıcı tedavilerin kullanım tipleri ve şekilleri kültürel, dinî ve coğrafi faktörlere göre değişiklik gösterir. Bu nedenle de ülkeden ülkeye farklılık gösterir. Bitkilerin bazıları geleneksel halk uygulamaları şeklinde bazıları da hekimlik uygulamalarında kullanılır. Deri hastalıklarında bitkisel tedaviler, topikal ya da sistemik yolla uygulanabilir. Her bitkinin kullanılacağı parçası ayrıdır: Yaprak, çiçek, kök vb. deri hastalıkları için bitkilerin kullanım şekilleri de özellik taşır: Bazıları hazırlanarak kullanılırken (suyu, yağı, ekstresi vb), bazıları da ilaç ruhsatı almıştır. İlaç ruhsatına en iyi örnek Behçet hastalığında kullanılan kolşisindir. İlaç dışındaki bitkisel ürünlerin içerikleri standart değildir. Yetiştiği coğrafya ya da iklime göre içerikleri değişiktir. Bu nedenle yan etkiler daha sık gözlenebilir ve bu yan etkiler hafif ya da ciddi olabilir. Bu yazıda, dermatolojide fitoterapiyle ilgili literatür (PubMed, Google Akademik) gözden geçirildi. Ülkemizde kolayca ulaşılabilecek bitkilere yer verildi. Dermatolojik hastalıklarda fitoterapi uygulamaları ana başlıklar altında anlatıldı: Akne, psöriyazis, vitiligo, verruka vulgaris, oral aft, pruritus, alopesi areata, uyuz ve bitlenme. Aknede; kekik, ısparta gülü, fesleğen yağı, yeşil çay, çay ağacı yağı, psöriyazisde; aloe vera, khellin, kapsaisin, vitiligoda; mabet ağacı, yerel kavun, khellin, yeşil çay, kapsaisin; verruka vulgaris ve kondiloma aküminatada ise podofilin yer almaktadır. Ayrıca Behçet hastalığında kolşisin, oral aft ve stomatitte kekik, kaşıntıda buğday kepeği, alopesi areatada sarımsak ekstresi, uyuz ve bitlenmede piretrinler bulunmaktadır.

Anahtar Kelimeler: Fitoterapi; deri hastalıkları
ABSTRACT
 Some of the dermatological diseases have a chronic course. The trend towards traditional and complementary treatment methods is higher in chronic skin diseases. The usage types and forms of traditional and complementary therapies vary according to cultural, religious and geographical factors. Therefore, it differs from country to country. Some of the plants are used in traditional folk practices and some are used in medical practices. In skin diseases, herbal treatments can be applied topically or systemically. The part of each plant to use is separate: Leaves, flowers, roots, etc. The use of plants for skin diseases also has features: Some of them are prepared before use (water, oil, essence, etc.), some others are licensed for medicine. The best example of medicine license is colchicine used in Behçet's disease. The contents of herbal products other than pharmaceuticals are not standard. Their contents are different depending on the geography or climate they grow. Therefore, side effects can be observed more frequently and can be mild or serious. In this article, the literature on phytotherapy in dermatology (PubMed, Google Academic) is reviewed. Plants that are easily accessible in our country were included. Phytotherapy applications in dermatological diseases are described under the main headings: Acne, psoriasis, vitiligo, verruca vulgaris, oral aft, pruritus, alopesia areata, scabies and lice. There are thyme, Rosa damascena, basil oil, green tea, tea tree oil in the acne; aloe vera, khellin, capsaicin in psoriasis; Ginkgo biloba, Cucumis melo, khellin, green tea, capsaicin in vitiligo; podophylline in verruca vulgaris and condyloma accuminata. Also there are colchicine in Behçet's disease; thyme in oral aphthae and stomatitis; wheat bran in itching; garlic extract in alopesia areata; pyrethrins in scabies and lice.

Keywords: Phytotherapy; skin disease
REFERENCES:
  1. Gül Ü. Dermatolojide alternatif tedavi yöntemleri. Türkiye Klinikleri Dermatoloji- Özel Konular. 2013;6(1).[Link] 
  2. Gönül M, Gül U, Cakmak SK, Kiliç S. Unconventional medicine in dermatology outpatients in Turkey. Int J Dermatol. 2009;48(6):639-44.[Crossref] [PubMed] 
  3. Bedi MK, Shenefelt PD. Herbal therapy in dermatology. Arch Dermatol. 2002;138(2):232-42.[Crossref] [PubMed] 
  4. agaclar.org [Internet]. [cited 05.05.2020]. Colchicum autumnale. Available from: [Link] 
  5. Colchicine. [cited 05.05.2020]. Available from: [Link] 
  6. Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment modalities for acne. Molecules. 2016;13;21(8):1063.[Crossref] [PubMed] [PMC] 
  7. Dodov MG, Kulevanova S. A review of phytotherapy of acne vulgaris. Macedonian Pharmaceutical Bulletin. 2009;55(1, 2):3-22.[Crossref] 
  8. Zu Y, Yu H, Liang L, Fu Y, Efferth T, Liu X, et al. Activities of ten essential oils towards Propionibacterium acnes and PC-3, A-549 and MCF-7 cancer cells. Molecules. 2010;30;15(5):3200-10.[Crossref] [PubMed] [PMC] 
  9. Zeybek U, Haksel M. Türkiye'de Ve Dünyada Önemli Tıbbi Bitkiler Ve Kullanımları. 1. Baskı. İzmir: Mesa Basım Matbaacılık; 2010.
  10. European Medicines Agency [Internet]. ©1995-2021 European Medicines Agency. [cited 05.05.2020]. Thymi herba. Available from: [Link] 
  11. T.C. Gümrük Ve Ticaret Bakanlığı Kooperatifçilik Genel Müdürlüğü. 2017 yılı gül çiçeği raporu. 2018. [cited 05.05.2020]. Available from: [Link] 
  12. Başer HC. Isparta gülü (Rosa damascena Mill.). Bağbahçe 46. 2013;(46):30-2.[Link] 
  13. Kılıç S, Okullu SÖ, Kurt Ö, Sevinç H, Dündar C, Altınordu F, et al. Efficacy of two plant extracts against acne vulgaris: initial results of microbiological tests and cell culture studies. J Cosmet Dermatol. 2019;18(4):1061-5.[Crossref] [PubMed] 
  14. Viyoch J, Pisutthanan N, Faikreua A, Nupangta K, Wangtorpol K, Ngokkuen J. Evaluation of in vitro antimicrobial activity of Thai basil oils and their micro-emulsion formulas against Propionibacterium acnes. Int J Cosmet Sci. 2006;28(2):125-33.[Crossref] [PubMed] 
  15. Orafidiya L, Agbani E, Oyedele A, Babalola O, Onayemi O. Preliminary clinical tests on topical preparations of Ocimum gratissimum Linn leaf essential oil for the treatment of acne vulgaris. Clin Drug Investig. 2002;22(5):313-9.[Crossref] 
  16. Orafidiya L, Agbani E, Oyedele A. The effect of aloe vera gel on the anti-acne properties of the essential oil of Ocimum gratissimum Linn leaf -a preliminary clinical investigation. International Journal of Aromatherapy. 2004;14(1):15-21.[Crossref] 
  17. Pazyar N, Feily A, Kazerouni A. Green tea in dermatology. Skinmed. 2012;10(6):352-5.[PubMed] 
  18. Tuong W, Walker L, Sivamani RK. Polyphenols as novel treatment options for dermatological diseases: A systematic review of clinical trials. J Dermatolog Treat. 2015;26(4):381-8.[Crossref] [PubMed] 
  19. Jung MK, Ha S, Son JA, Song JH, Houh Y, Cho E, et al. Polyphenon-60 displays a therapeutic effect on acne by suppression of TLR2 and IL-8 expression via down-regulating the ERK1/2 pathway. Arch Dermatol Res. 2012;304(8):655-63.[Crossref] [PubMed] 
  20. Yoon JY, Kwon HH, Min SU, Thiboutot DM, Suh DH. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol. 2013;133(2):429-40.[Crossref] [PubMed] 
  21. Mahmood T, Akhtar N, Khan BA, Khan HM, Saeed T. Outcomes of 3% green tea emulsion on skin sebum production in male volunteers. Bosn J Basic Med Sci. 2010;10(3):260-4.[Crossref] [PubMed] [PMC] 
  22. Liao S. The medicinal action of androgens and green tea epigallocatechin gallate. Hong Kong Med J. 2001;7(4):369-74.[PubMed] 
  23. Lu PH, Hsu CH. Does supplementation with green tea extract improve acne in post-adolescent women? A randomized, double-blind, and placebo-controlled clinical trial. Complement Ther Med. 2016;25:159-63.[Crossref] [PubMed] 
  24. Elsaie ML, Abdelhamid MF, Elsaaiee LT, Emam HM. The efficacy of topical 2% green tea lotion in mild-to-moderate acne vulgaris. J Drugs Dermatol. 2009;8(4):358-64.[PubMed] 
  25. Saric S, Notay M, Sivamani RK. Green tea and other tea polyphenols: effects on sebum production and acne vulgaris. Antioxidants (Basel). 2016;29;6(1):2.[Crossref] [PubMed] [PMC] 
  26. Ergin K, Yaylalı A. [A review about resveratrol and it’s effects]. S.D.Ü. Tıp Fak Derg. 2013;20(3):115-20.[Link] 
  27. Vestergaard M, Ingmer H. Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents. 2019;53(6):716-23.[Crossref] [PubMed] 
  28. Taylor EJ, Yu Y, Champer J, Kim J. Resveratrol demonstrates antimicrobial effects against propionibacterium acnes İn vitro. Dermatol Ther (Heidelb). 2014;4(2):249-57.[Crossref] [PubMed] [PMC] 
  29. Kim SY, Hyun MY, Go KC, Zouboulis CC, Kim BJ. Resveratrol exerts growth inhibitory effects on human SZ95 sebocytes through the inactivation of the PI3-K/Akt pathway. Int J Mol Med. 2015;35(4):1042-50.[Crossref] [PubMed] 
  30. Soleymani S, Iranpanah A, Najafi F, Belwal T, Ramola S, Abbasabadi Z, et al. Implications of grape extract and its nanoformulated bioactive agent resveratrol against skin disorders. Arch Dermatol Res. 2019;311(8):577-88.[Crossref] [PubMed] 
  31. Fabbrocini G, Staibano S, De Rosa G, Battimiello V, Fardella N, Ilardi G, ET AL. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. Am J Clin Dermatol. 2011;1;12(2):133-41.[Crossref] [PubMed] 
  32. Bagherani N, Smoller BR. Role of tea tree oil in treatment of acne. Dermatol Ther. 2015;28(6):404.[Crossref] [PubMed] 
  33. Hammer KA. Treatment of acne with tea tree oil (melaleuca) products: a review of efficacy, tolerability and potential modes of action. Int J Antimicrob Agents. 2015;45(2):106-10.[Crossref] [PubMed] 
  34. Malhi HK, Tu J, Riley TV, Kumarasinghe SP, Hammer KA. Tea tree oil gel for mild to moderate acne; a 12 week uncontrolled, open-label phase II pilot study. Australas J Dermatol. 2017;58(3):205-10.[Crossref] [PubMed] 
  35. Enshaieh S, Jooya A, Siadat AH, Iraji F. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Indian J Dermatol Venereol Leprol. 2007;73(1):22-5.[Crossref] [PubMed] 
  36. Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. Med J Aust. 1990;15;153(8):455-8.[Crossref] [PubMed] 
  37. Mazzarello V, Donadu MG, Ferrari M, Piga G, Usai D, Zanetti S, et al. Treatment of acne with a combination of propolis, tea tree oil, and Aloe vera compared to erythromycin cream: two double-blind investigations. Clin Pharmacol. 2018;13;10:175-81.[Crossref] [PubMed] [PMC] 
  38. Rani A, Sharma A. The genus vitex: a review. Pharmacogn Rev. 2013;7(14):188-98.[Crossref] [PubMed] [PMC] 
  39. Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 2005;28(4):319-32.[Crossref] [PubMed] 
  40. Ernst E. The usage of complementary therapies by dermatological patients: a systematic review. Br J Dermatol. 2000;142(5):857-61.[Crossref] [PubMed] 
  41. Gönül M, Çakmak, SK, Gül Ü, Bıyıklı Z. What do patients with psoriasis think about the causes of their disease and use for psoriasis? TANG Humanitas Medicine. 2012;2(1):1-4.[Crossref] 
  42. Gabr SA, Alghadir AH. Phytotherapy and psoriasis: Complementary and alternative medications. World J Dermatol. 2014;3(4):86-91.[Crossref] 
  43. Farahnik B, Sharma D, Alban J, Sivamani RK. Topical botanical agents for the treatment of psoriasis: a systematic review. Am J Clin Dermatol. 2017;18(4):451-68.[Crossref] [PubMed] 
  44. BITKIVT|Online Bitki Veritabanı [Internet]. ©Hayriye EŞBAH TUNÇAY, Muhammed Ali ÖRNEK, Meliz AKYOL. [cited 05.05.2020]. Veritabanında yer alan tüm bitkilerin alfabetik sıralı listesi. Available from: [Link] 
  45. ClinicalTrials.gov [Internet]. [cited 05.05.2020]. Psoriasis Indigo Naturalis Chinese Medicine Medicated Bath. Available from: [Link] 
  46. Cheng HM, Wu YC, Wang Q, Song M, Wu J, Chen D, et al. Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis. BMC Complement Altern Med. 2017;2;17(1):439.[Crossref] [PubMed] [PMC] 
  47. Deng S, May BH, Zhang AL, Lu C, Xue CC. Phytotherapy in the management of psoriasis: a review of the efficacy and safety of oral interventions and the pharmacological actions of the main plants. Arch Dermatol Res. 2014;306(3):211-29.[Crossref] [PubMed] 
  48. Tse TW. Use of common Chinese herbs in the treatment of psoriasis. Clin Exp Dermatol. 2003;28(5):469-75.[Crossref] [PubMed] 
  49. Male? Ž, Drvar DL, Duka I, Žužul K. Application of medicinal plants in several dermatovenerological entities. Acta Pharm. 2019;1;69(4):525-31.[Crossref] [PubMed] 
  50. Foulkes AC, Grindlay DJ, Griffiths CE, Warren RB. What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. Clin Exp Dermatol. 2011;36(6):585-9; quiz 588-9.[Crossref] [PubMed] 
  51. Miroddi M, Navarra M, Calapai F, Mancari F, Giofrè SV, Gangemi S, et al. Review of clinical pharmacology of Aloe vera L. in the Treatment of Psoriasis. Phytother Res. 2015;29(5):648-55.[Crossref] [PubMed] 
  52. Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. Trop Med Int Health. 1996;1(4):505-9.[Crossref] [PubMed] 
  53. Paulsen E, Korsholm L, Brandrup F. A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2005;19(3):326-31.[Crossref] [PubMed] 
  54. Choonhakarn C, Busaracome P, Sripanidkulchai B, Sarakarn P. A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2010;24(2):168-72.[Crossref] [PubMed] 
  55. Dong X, Zeng Y, Liu Y, You L, Yin X, Fu J, et al. Aloe-emodin: a review of its pharmacology, toxicity, and pharmacokinetics. Phytother Res. 2020;34(2):270-81.[Crossref] [PubMed] 
  56. Divya G, Panonnummal R, Gupta S, Jayakumar R, Sabitha M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur J Pharm Biopharm. 2016;107:97-109.[Crossref] [PubMed] 
  57. Drugs.com [Internet]. ©2000-2020 Drugs.com. [cited 05.05.2020]. Khella. Available from: [Link] 
  58. Alam S, Anjum N, Akhtar J, Bashir F. Pharmacological investigations on Khella- (Ammi visnaga L.). World Journal of Pharmaceutical Research. 2018;7(13):212-24.[Link] 
  59. Abdel-Fattah A, Aboul-Enein MN, Wassel G, El-Menshawi B. Preliminary report on the therapeutic effect of khellin in psoriasis. Dermatologica. 1983;167(2):109-10.[Crossref] [PubMed] 
  60. Boyd K, Shea SM, Patterson JW. The role of capsaicin in dermatology. Prog Drug Res. 2014;68:293-306.[Crossref] [PubMed] 
  61. Drugs.com [Internet]. ©2000-2020 Drugs.com. [cited 05.05.2020]. Capsaicin. Available from: [Link] 
  62. Arnold WP, van de Kerkhof PC. Topical capsaicin in pruritic psoriasis. J Am Acad Dermatol. 1994;31(1):135.[Crossref] [PubMed] 
  63. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol. 1993;29(3):438-42.[Crossref] [PubMed] 
  64. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol. 1986;15(3):504-7.[Crossref] [PubMed] 
  65. European Medicines Agency [Internet]. [cited 05.05.2020]. Assessment report on Arnica montana L. Available from: [Link] 
  66. Hörmann HP, Korting HC. Evidence for the efficacy and safety of topical herbal drugs in dermatology: part I: anti-inflammatory agents. Phytomedicine. 1994;1(2):161-71.[Crossref] [PubMed] 
  67. Gianfaldoni S, Wollina U, Tirant M, Tchernev G, Lotti J, Satolli F, et al. Herbal compounds for the treatment of vitiligo: a review. Open Access Maced J Med Sci. 2018;21;6(1):203-7.[Crossref] [PubMed] [PMC] 
  68. European Medicines Agency [Internet]. [cited 05.05.2020]. European Union herbal monograph on Ginkgo biloba L.,folium. Available from: [Link] 
  69. Drug.com [Internet]. ©2000-2020 Drugs.com. [cited 05.05.2020]. Gingko biloba. Available from: [Link] 
  70. Zhang S, Yi X, Su X, Jian Z, Cui T, Xiao Q, et al. Ginkgo biloba extract protects human melanocytes from H(2) O(2) -induced oxidative stress by activating Nrf2. J Cell Mol Med. 2019;23(8):1-7.[Crossref] [PubMed] [PMC] 
  71. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med. 2011;15;11:21.[Crossref] [PubMed] [PMC] 
  72. Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2003;28(3):285-7.[Crossref] [PubMed] 
  73. Drugs.com [Internet]. ©2000-2020 Drugs.com. [cited 05.05.2020]. Turmeric. Available from: [Link] 
  74. Schallreuter KU, Panske A, Chiuchiarelli G. Ineffective topical treatment of vitiligo with Cucumis melo extracts. Int J Dermatol. 2011;50(3):374-5.[Crossref] [PubMed] 
  75. Buggiani G, Tsampau D, Hercogovà J, Rossi R, Brazzini B, Lotti T. Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients. Dermatol Ther. 2012;25(5):472-6.[Crossref] [PubMed] 
  76. Carlie G, Ntusi NB, Hulley PA, Kidson SH. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro. Br J Dermatol. 2003;149(4):707-17.[Crossref] [PubMed] 
  77. Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol. 2004;29(2):180-4.[Crossref] [PubMed] 
  78. Hofer A, Kerl H, Wolf P. Long-term results in the treatment of vitiligo with oral khellin plus UVA. Eur J Dermatol. 2001;11(3):225-9.[PubMed] 
  79. Fenniche S, Zaouak A, Tanfous AB, Jrad M, Hammami H. Successful treatment of refractory vitiligo with a combination of khellin and 308-nm excimer lamp: an open-label, 1-year prospective study. Dermatol Ther (Heidelb). 2018;8(1):127-35.[Crossref] [PubMed] [PMC] 
  80. Bagherani N. The efficacy of 308 nm UV excimer light as monotherapy and combination therapy with topical khellin 4% and/or tacrolimus 0.1% in the treatment of vitiligo. Dermatol Ther. 2016;29(2):137-8.[Crossref] [PubMed] 
  81. Buchness MR. Alternative medicine and dermatology. Semin Cutan Med Surg. 1998;17(4):284-90.[Crossref] [PubMed] 
  82. Becatti M, Prignano F, Fiorillo C, Pescitelli L, Nassi P, Lotti T, et al. The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin. Antioxid Redox Signal. 2010;1;13(9):1309-21.[Crossref] [PubMed] 
  83. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195-218.[Crossref] [PubMed] [PMC] 
  84. Schallreuter KU, Rokos H. Turmeric (curcumin): a widely used curry ingredient, can contribute to oxidative stress in Asian patients with acute vitiligo. Indian J Dermatol Venereol Leprol. 2006;72(1):57-9.[Crossref] [PubMed] 
  85. Asawanonda P, Klahan SO. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study. Photomed Laser Surg. 2010;28(5):679-84.[Crossref] [PubMed] 
  86. Bedows E, Hatfield GM. An investigation of the antiviral activity of Podophyllum peltatum. J Nat Prod. 1982;45(6):725-9.[Crossref] [PubMed] 
  87. Drugs.com [Internet]. ©2000-2020 Drugs.com. [cited 05.05.2020]. Podophyllum resin. Available from: [Link] 
  88. Sterling JC, Gibbs S, Hussain SSH, et al. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014;171(4):696-712.[Crossref] [PubMed] 
  89. White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study. Genitourin Med. 1997;73(3):184-7.[Crossref] [PubMed] [PMC] 
  90. McDow RA. Cryosurgery and podophyllum in combination for condylomata. Am Fam Physician. 1996;1;53(6):1987-8, 1993.[PubMed] 
  91. Fisher AA. Severe systemic and local reactions to topical podophyllum resin. Cutis. 1981;28(3):233, 236, 242 passim.[PubMed] 
  92. (05.05.2020 tarihinde alıntılandı).[Link] 
  93. Bhat A, Naguwa SM, Cheema GS, Gershwin ME. Colchicine revisited. Ann N Y Acad Sci. 2009;1173:766-73.[Crossref] [PubMed] 
  94. Karamanou M, Tsoucalas G, Pantos K, Androutsos G. Isolating colchicine in 19th century: an old drug revisited. Curr Pharm Des. 2018;24(6):654-8.[Crossref] [PubMed] 
  95. Teresa A, Krishnakumar K, Kumar D, John A. Herbal remedıes for mouth ulcer: a review. J Bio Innov. 2017;6(4):521-7.
  96. European Medicines Agency [Internet]. Assessment report on Thymus vulgaris L., vulgaris zygis L., herba. (05.05.2020 tarihinde alıntılandı).[Link] 
  97. Kömürcü İS. Farklı hububat kepeklerinin ekmek kalitesine etkileri. Yüksek Lisans Tezi. İstanbul: İstanbul Teknik Üniversitesi Fen Bilimleri Enstitüsü; 2005.[Link] 
  98. Maluki AH, Mahmood TA, Hadi QN. Treatment of alopecia areata with topical garlic extract. Kufa Med Journal. 2009;12(1):330-6.[Link] 
  99. CLISHEA.CO [Internet]. ©2020, clishea.co. [cited 05.05.2020]. How to use garlic in treating alopecia areata. Available from: [Link] 
  100. Drugs.com [Internet]. ©2000-2020 Drugs.com. [cited 05.05.2020]. Pyrethrins. Available from: [Link] 
  101. Türkiye Acil Tıp Derneği [Internet]. Köse A, Denizbaşı A. Piretrin ve piretroid grubu insektisidler.[cited 05.05.2020]. Available from: [Link] 
  102. Korkmaz M. [Emerging importance of repellents and new approaches to the treatment of scabies and pediculosis]. ANKEM Derg. 2009;23(Ek 2):228-32.[Link] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com